Alzheimer’s may begin to shrink two areas of the brain years before memory loss

Alzheimer’s disease may begin to leave visible traces on the brain ten years before memory problems appear. Johns Hopkins University researchers have identified two brain regions that show signs of degeneration before the hippocampus, which is an area that is often examined for evidence of the disease.
The discovery could help doctors detect Alzheimer’s years before symptoms begin, which could allow treatment to begin when there is the greatest chance of protecting the brain.
By examining hundreds of brain scans, scientists found that the entorhinal cortex and amygdala, two regions involved in memory and emotion, begin to lose tissue before the hippocampus. These changes may provide important new clues about how Alzheimer’s develops and how it can be detected before significant cognitive decline occurs.
“We found that there are early changes in the brain that show clinical signs of atrophy about ten years before there are clinical symptoms,” said biomedical engineer and senior author Michael Miller. “At least a game of 5-to-10 years in which your brain changes. Just imagine if we can start treating neurodegenerative changes at 2, 3 or 4-point of age rather than after 15 years when the changes are visible in memory symptoms. That is a big promise here for your vulnerable loved ones.”
The findings were recently published in NeuroImage Reports and presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.
Detecting Alzheimer’s Before Memory Loss
Alzheimer’s is the most common cause of dementia worldwide, but the disease does not begin when a person first experiences forgetfulness or confusion. Changes associated with Alzheimer’s can accumulate in the brain decades before visible symptoms appear.
Scientists believe that this long period of silence may provide an important opportunity for treatment. Early intervention before serious damage occurs can do more to preserve memory and other cognitive abilities. However, taking advantage of that opportunity requires reliable methods to diagnose the disease in its early stages.
Another promising approach involves biomarkers, measurable biological changes that can indicate the presence or progression of a disease. In Alzheimer’s research, these markers can help identify who is developing the disease before symptoms appear.
“Our goal is to be able to treat people before Alzheimer’s symptoms develop so they can be delayed or stopped,” said Marilyn Albert, author and director of the Johns Hopkins Alzheimer’s Disease Research Center.
Two Brain Regions Reveal Early Warning Signs
To investigate where early changes appear to occur, researchers examined hundreds of magnetic resonance imaging (MRI) and positron emission tomography (PET) scans collected by two independent research projects: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study.
The scans followed people in different stages of Alzheimer’s disease over time, including people without symptoms, those with cognitive impairment, and patients who eventually died of the disease.
In both groups, the researchers observed a consistent pattern. The entorhinal cortex and the amygdala, which are located near the hippocampus, showed a greater loss of related tissue during the onset of Alzheimer’s than the hippocampus itself.
This distinction is important because the hippocampus plays an important role in memory and has traditionally been the focus of attention when doctors look for Alzheimer’s-related brain damage.
The two regions that have just been highlighted are performing their important functions. The entorhinal cortex helps retrieve previously stored memories, while the amygdala contributes to emotional memory, including how emotional experiences are processed and remembered.
Their earlier decline suggests that examining these structures together may reveal signs of Alzheimer’s that may go unnoticed when attention is focused primarily on the hippocampus.
Brain Shrinkage Linked to Alzheimer’s Tau Protein
The researchers also found a significant link between the loss of brain tissue and tau, a protein closely related to Alzheimer’s disease.
Under normal conditions, tau helps maintain the inner structure of nerve cells. In Alzheimer’s, however, tau can accumulate abnormally and form tangles that interfere with healthy brain function.
Using PET imaging and digital pathology, the scientists found that the shrinking gray areas overlapped with regions showing tau-related changes. Gray matter contains many nerve cell bodies and is important for processing information throughout the brain.
This relationship reinforces the possibility that changes in the entorhinal cortex and amygdala may serve as useful indicators of early Alzheimer’s disease.
The team believes that measuring tissue loss in both regions, rather than relying primarily on changes in the hippocampus, could ultimately improve the prediction of who is likely to develop cognitive decline.
As brain imaging becomes more accessible and less expensive, this approach may also become more effective. For people with a family history of Alzheimer’s or other risk factors, researchers envision a future where doctors may be able to diagnose these regions as early as a person’s 30s or 40s.
“As biomarkers and treatments become increasingly available, knowing who will have cognitive decline will become increasingly important,” said co-author Meaghan Morris, a neuropathologist who studies Alzheimer’s and other dementias. “This could play a better role in risk stratification to identify who will develop dementia in the near future – and treat people earlier and earlier to delay the progression of the disease.”
A Potential New Approach Toward Early Treatment of Alzheimer’s
Although the findings are promising, more research is needed before doctors can use these brain changes as a reliable diagnostic tool. Research identifies potential early biomarkers, but has not yet established a clinical test that can predict Alzheimer’s age in advance.
The next step is to investigate what is happening within these regions on a much smaller scale. Researchers want to understand the molecular changes surrounding abnormal tau accumulation and how those changes contribute to the progressive loss of brain tissue.
Identifying the biological processes involved may ultimately yield new targets for therapies designed to interrupt Alzheimer’s before serious damage occurs.
“Our future work is to better characterize the molecular areas associated with these Tau protein changes as localized by these clinical signs of atrophy,” Miller said. “Once we know more about the molecular environment, we can develop treatments.”
Source link

